These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Computational Drug Design Applied to the Study of Metabotropic Glutamate Receptors. Llinas Del Torrent C; Pérez-Benito L; Tresadern G Molecules; 2019 Mar; 24(6):. PubMed ID: 30897742 [TBL] [Abstract][Full Text] [Related]
4. Potential for the Rational Design of Allosteric Modulators of Class C GPCRs. Christopher JA; Doré AS; Tehan BG Curr Top Med Chem; 2017; 17(1):71-78. PubMed ID: 27448651 [TBL] [Abstract][Full Text] [Related]
5. Selective Negative Allosteric Modulation Of Metabotropic Glutamate Receptors – A Structural Perspective of Ligands and Mutants. Harpsøe K; Isberg V; Tehan BG; Weiss D; Arsova A; Marshall FH; Bräuner-Osborne H; Gloriam DE Sci Rep; 2015 Sep; 5():13869. PubMed ID: 26359761 [TBL] [Abstract][Full Text] [Related]
10. Subtype-selective mechanisms of negative allosteric modulators binding to group I metabotropic glutamate receptors. Fu TT; Tu G; Ping M; Zheng GX; Yang FY; Yang JY; Zhang Y; Yao XJ; Xue WW; Zhu F Acta Pharmacol Sin; 2021 Aug; 42(8):1354-1367. PubMed ID: 33122823 [TBL] [Abstract][Full Text] [Related]
11. Covalent Allosteric Probe for the Metabotropic Glutamate Receptor 2: Design, Synthesis, and Pharmacological Characterization. Doornbos MLJ; Wang X; Vermond SC; Peeters L; Pérez-Benito L; Trabanco AA; Lavreysen H; Cid JM; Heitman LH; Tresadern G; IJzerman AP J Med Chem; 2019 Jan; 62(1):223-233. PubMed ID: 29494768 [TBL] [Abstract][Full Text] [Related]
12. Asymmetric activation of dimeric GABA Liu L; Lin L; Shen C; Rondard P; Pin JP; Xu C; Liu J Am J Physiol Cell Physiol; 2023 Jul; 325(1):C79-C89. PubMed ID: 37184233 [TBL] [Abstract][Full Text] [Related]
13. Structure of a class C GPCR metabotropic glutamate receptor 1 bound to an allosteric modulator. Wu H; Wang C; Gregory KJ; Han GW; Cho HP; Xia Y; Niswender CM; Katritch V; Meiler J; Cherezov V; Conn PJ; Stevens RC Science; 2014 Apr; 344(6179):58-64. PubMed ID: 24603153 [TBL] [Abstract][Full Text] [Related]
15. Allosteric Modulation of Class A GPCRs: Targets, Agents, and Emerging Concepts. Wold EA; Chen J; Cunningham KA; Zhou J J Med Chem; 2019 Jan; 62(1):88-127. PubMed ID: 30106578 [TBL] [Abstract][Full Text] [Related]
16. Leveraging allostery to improve G protein-coupled receptor (GPCR)-directed therapeutics: cannabinoid receptor 1 as discovery target. Janero DR; Thakur GA Expert Opin Drug Discov; 2016 Dec; 11(12):1223-1237. PubMed ID: 27712124 [TBL] [Abstract][Full Text] [Related]
17. The computational modeling of allosteric modulation of metabotropic glutamate receptors. Pérez-Benito L; Llinas Del Torrent C; Pardo L; Tresadern G Adv Pharmacol; 2020; 88():1-33. PubMed ID: 32416864 [TBL] [Abstract][Full Text] [Related]
18. Fragment-Based Approaches for Allosteric Metabotropic Glutamate Receptor (mGluR) Modulators. Orgován Z; Ferenczy GG; Keserű GM Curr Top Med Chem; 2019; 19(19):1768-1781. PubMed ID: 31393248 [TBL] [Abstract][Full Text] [Related]
19. Allosteric inhibition of g-protein coupled receptor oligomerization: strategies and challenges for drug development. Hurevich M; Talhami A; Shalev DE; Gilon C Curr Top Med Chem; 2014; 14(15):1842-63. PubMed ID: 25175995 [TBL] [Abstract][Full Text] [Related]
20. Allosteric modulation of GPCRs: From structural insights to in silico drug discovery. Persechino M; Hedderich JB; Kolb P; Hilger D Pharmacol Ther; 2022 Sep; 237():108242. PubMed ID: 35863587 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]